Last $31.27 USD
Change Today -0.035 / -0.11%
Volume 479.8K
THOR On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 11/25/14 All times are local (Market data is delayed by at least 15 minutes).

thoratec corp (THOR) Snapshot

Open
$31.34
Previous Close
$31.30
Day High
$31.49
Day Low
$30.91
52 Week High
11/27/13 - $43.00
52 Week Low
08/7/14 - $22.50
Market Cap
1.7B
Average Volume 10 Days
1.0M
EPS TTM
$0.97
Shares Outstanding
55.0M
EX-Date
--
P/E TM
32.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for THORATEC CORP (THOR)

thoratec corp (THOR) Related Businessweek News

No Related Businessweek News Found

thoratec corp (THOR) Details

Thoratec Corporation develops, manufactures, and markets proprietary medical devices used for mechanical circulatory support for the treatment of heart failure patients. The company’s primary product lines include ventricular assist devices, such as HeartMate II, an implantable left ventricular assist device consisting of a rotary blood pump to provide intermediate and long-term mechanical circulatory support (MCS); and HeartMate XVE, an implantable and pulsatile left ventricular assist device for intermediate and longer-term MCS. Its ventricular assist devices also comprise CentriMag, an extracorporeal full-flow acute surgical support platform that offers support up to 30 days for cardiac and respiratory failure; and PediMag and PediVAS extracorporeal full-flow acute surgical support platforms designed to provide acute surgical support to pediatric patients. In addition, the company provides Paracorporeal Ventricular Assist Device, an external pulsatile ventricular assist device, which provides left, right, and biventricular MCS approved for bridge-to-transplantation (BTT), including home discharge and post-cardiotomy myocardial recovery; and Implantable Ventricular Assist Device, an implantable and pulsatile ventricular assist device designed to provide left, right, and biventricular MCS approved for BTT comprising home discharge and post-cardiotomy myocardial recovery. It sells its products through direct sales force and distributors in the United States and internationally. Thoratec Corporation was founded in 1976 and is headquartered in Pleasanton, California.

951 Employees
Last Reported Date: 02/18/14
Founded in 1976

thoratec corp (THOR) Top Compensated Officers

Chief Financial Officer and Vice President
Total Annual Compensation: $302.3K
Senior Vice President and General Counsel
Total Annual Compensation: $338.3K
Advisor
Total Annual Compensation: $570.7K
Compensation as of Fiscal Year 2013.

thoratec corp (THOR) Key Developments

Thoratec Corp. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 27, 2014; Revises Earnings Guidance for the Fiscal 2014

Thoratec Corp. reported unaudited consolidated earnings results for the third quarter and nine months ended September 27, 2014. For the quarter, the company reported net income of $2,897,000 or $0.05 diluted earnings per share on product sales of $105,839,000 against net income of $18,904,000 or $0.32 diluted earnings per share on product sales of $126,444,000 a year ago. Income from operations was $2,111,000 and income before income taxes was $984,000 against income from operations of $22,338,000 and income before income taxes of $22,907,000 a year ago. On non-GAAP basis, the company reported net income of $10,161,000 or $0.18 diluted per share against $28,475,000 or $0.49 diluted per share a year ago. For nine months, the company reported net income of $38,549,000 or $0.68 diluted earnings per share on product sales of $349,599,000 against net income of $60,263,000 or $1.05 diluted earnings per share on product sales of $374,648,000 a year ago. Income from operations was $54,173,000 and income before income taxes was $53,850,000 against income from operations of $78,781,000 and income before income taxes of $80,676,000 a year ago. On non-GAAP basis, the company reported net income of $58,241,000 or $1.02 diluted per share against $82,802,000 or $1.42 diluted per share a year ago. The company adjusts full-year 2014 guidance for revenue to a range of $450 million to $460 million and for net income per diluted share to $0.70 to $0.80 on a GAAP basis and $1.20 to $1.30 on a non-GAAP basis. Gross margin is expected to be 66.8% to 67.3% on a GAAP basis and 68.5% to 69.0% on a non-GAAP basis. The company expects the effective tax rate to be 26.5% to 27.5% on a GAAP basis and 29% to 30% on a non-GAAP basis.

Thoratec Corp. Presents at Credit Suisse Annual Healthcare Conference, Nov-12-2014 10:00 AM

Thoratec Corp. Presents at Credit Suisse Annual Healthcare Conference, Nov-12-2014 10:00 AM. Venue: The Biltmore, 2400 E Missouri Ave, Phoenix, AZ 85016, United States. Speakers: D. Keith Grossman, Chief Executive Officer, President and Director.

Thoratec Corp. to Report Q3, 2014 Results on Nov 05, 2014

Thoratec Corp. announced that they will report Q3, 2014 results at 8:02 PM, GMT Standard Time on Nov 05, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
THOR:US $31.27 USD -0.035

THOR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cyberonics Inc $53.76 USD -0.50
ICU Medical Inc $83.63 USD -0.06
Merit Medical Systems Inc $15.12 USD +0.12
Tornier NV $26.88 USD +0.57
Wright Medical Group Inc $29.22 USD +0.51
View Industry Companies
 

Industry Analysis

THOR

Industry Average

Valuation THOR Industry Range
Price/Earnings 34.3x
Price/Sales 3.6x
Price/Book 2.6x
Price/Cash Flow 32.9x
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THORATEC CORP, please visit www.thoratec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.